otamixaban
Sign in to saveOtamixaban (INN) is an experimental injectable anticoagulant direct factor Xa inhibitor that was investigated for the treatment for acute coronary syndrome. In 2013, Sanofi announced that it had ended development of the drug candidate after poor performance in a Phase III clinical trial.
Research
62 papers- The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development.Current medicinal chemistry · 2007
- Otamixaban in acute coronary syndromes.Lancet (London, England) · 2009
- Drug evaluation: the directly activated Factor Xa inhibitor otamixaban.IDrugs : the investigational drugs journal · 2006
- Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial.Lancet (London, England) · 2009
- Synergistic inhibition of SARS-CoV-2 cell entry by otamixaban and covalent protease inhibitors: pre-clinical assessment of pharmacological and molecular properties.Chemical science · 2021
via PubMed
Wikidata facts
- Mass
- 446.195
Show 4 more facts
- chemical formula
- C₂₅H₂₆N₄O₄
- Commons category
- Otamixaban
- canonical SMILES
- CC(C(CC1=CC=CC(=C1)C(=N)N)C(=O)OC)NC(=O)C2=CC=C(C=C2)C3=CC=[N+](C=C3)[O-]
- isomeric SMILES
- C[C@H]([C@@H](CC1=CC=CC(=C1)C(=N)N)C(=O)OC)NC(=O)C2=CC=C(C=C2)C3=CC=[N+](C=C3)[O-]
via Wikidata · CC0
~2 min read
Article
1 sectionsContents
- References
{{Drugbox | Verifiedfields = changed | verifiedrevid = 462266309 | IUPAC_name = Methyl (2R,3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate | image = Otamixaban.svg | image_class = skin-invert-image | image2 = Otamixaban 3D.png | image_class2 = bg-transparent
| tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration =